Cellular xenotransplantation of animal cells into people: benefits and risk

Linda Scobie, Cesare Galli, Pierre Gianello, Emanuele Cozzi, H.-J. Schuurman

Research output: Chapter in Book/Report/Conference proceedingChapter (peer-reviewed)

18 Downloads (Pure)

Abstract

The main benefit of xenotransplantation is its potential to overcome the worldwide organ shortage experienced in allotransplantation. Allogeneic transplantation is the only successful therapy for several life-threatening diseases, with cell, tissue or organ donation only partially meeting the demand and many patients dying while waiting for treatment. With supply falling short of demand, it is foreseen that the use of porcine material may at some stage overcome the existing gap between organ availability and clinical need. Recently, pig islet cells have been utilised in clinical trials, with safety being demonstrated. Indeed, pig-derived cells present several advantages: i) porcine cells have a stable function and differentiation pattern and are not tumorigenic; ii) pig cells have been shown to meet the physiological needs in large animal models; iii) the source of pig cells can be scaled up to meet demands in a highly standardised manner, and with respect to animal welfare regulations; iv) ‘designated-pathogen-free’ (DPF) pig lines can be produced, which could result in a higher safety profile than allotransplantation itself; v) the risk of zoonosis, which was raised years ago as the major hurdle, has been recently circumvented and is actually viewed as a controlled risk; and vi) immune risks are being circumvented via the use of genetically modified donor animals and encapsulation of porcine cells, particularly for the treatment of diabetes. Overall, the benefit appears to outweigh potential risks with respect to cellular xenotransplantation and this is discussed further in this review.
Original languageEnglish
Title of host publicationScientific and Technical Review
PublisherOIE
Pages113-122
Volume37
ISBN (Print)978-92-95108-54-7
DOIs
Publication statusPublished - 30 Apr 2018

Fingerprint

Heterologous Transplantation
Swine
Tissue and Organ Procurement
Safety
Animal Welfare
Genetically Modified Animals
Homologous Transplantation
Zoonoses
Islets of Langerhans
Therapeutics
Animal Models
Tissue Donors
Clinical Trials

Keywords

  • xenotransplantation
  • animal cells

Cite this

Scobie, L., Galli, C., Gianello, P., Cozzi, E., & Schuurman, H-J. (2018). Cellular xenotransplantation of animal cells into people: benefits and risk. In Scientific and Technical Review (Vol. 37, pp. 113-122). OIE. https://doi.org/10.20506/rst.37.1.2744
Scobie, Linda ; Galli, Cesare ; Gianello, Pierre ; Cozzi, Emanuele ; Schuurman, H.-J. / Cellular xenotransplantation of animal cells into people: benefits and risk. Scientific and Technical Review. Vol. 37 OIE, 2018. pp. 113-122
@inbook{c59a3700047c46a6a9043598a27ff4e3,
title = "Cellular xenotransplantation of animal cells into people: benefits and risk",
abstract = "The main benefit of xenotransplantation is its potential to overcome the worldwide organ shortage experienced in allotransplantation. Allogeneic transplantation is the only successful therapy for several life-threatening diseases, with cell, tissue or organ donation only partially meeting the demand and many patients dying while waiting for treatment. With supply falling short of demand, it is foreseen that the use of porcine material may at some stage overcome the existing gap between organ availability and clinical need. Recently, pig islet cells have been utilised in clinical trials, with safety being demonstrated. Indeed, pig-derived cells present several advantages: i) porcine cells have a stable function and differentiation pattern and are not tumorigenic; ii) pig cells have been shown to meet the physiological needs in large animal models; iii) the source of pig cells can be scaled up to meet demands in a highly standardised manner, and with respect to animal welfare regulations; iv) ‘designated-pathogen-free’ (DPF) pig lines can be produced, which could result in a higher safety profile than allotransplantation itself; v) the risk of zoonosis, which was raised years ago as the major hurdle, has been recently circumvented and is actually viewed as a controlled risk; and vi) immune risks are being circumvented via the use of genetically modified donor animals and encapsulation of porcine cells, particularly for the treatment of diabetes. Overall, the benefit appears to outweigh potential risks with respect to cellular xenotransplantation and this is discussed further in this review.",
keywords = "xenotransplantation, animal cells",
author = "Linda Scobie and Cesare Galli and Pierre Gianello and Emanuele Cozzi and H.-J. Schuurman",
note = "Acceptance in SAN (author didn't receive formal acceptance and this is closest to this). ET 3/10/18 AAM: author confirmed version, removed track changes. ET 2/10/18 AAM: No info in Sherpa, used 12m embargo as noted on webpage: 'Articles are generally available in full text after a 12-month delay (embargo); however, the delay may vary at the discretion of the publisher.' Exception form sent ET 8/10/18; author confirmed book chapter and provided exception information. Author email in SAN in case we need to use this later. ET 9/10/18",
year = "2018",
month = "4",
day = "30",
doi = "10.20506/rst.37.1.2744",
language = "English",
isbn = "978-92-95108-54-7",
volume = "37",
pages = "113--122",
booktitle = "Scientific and Technical Review",
publisher = "OIE",

}

Scobie, L, Galli, C, Gianello, P, Cozzi, E & Schuurman, H-J 2018, Cellular xenotransplantation of animal cells into people: benefits and risk. in Scientific and Technical Review. vol. 37, OIE, pp. 113-122. https://doi.org/10.20506/rst.37.1.2744

Cellular xenotransplantation of animal cells into people: benefits and risk. / Scobie, Linda; Galli, Cesare; Gianello, Pierre ; Cozzi, Emanuele; Schuurman, H.-J.

Scientific and Technical Review. Vol. 37 OIE, 2018. p. 113-122.

Research output: Chapter in Book/Report/Conference proceedingChapter (peer-reviewed)

TY - CHAP

T1 - Cellular xenotransplantation of animal cells into people: benefits and risk

AU - Scobie, Linda

AU - Galli, Cesare

AU - Gianello, Pierre

AU - Cozzi, Emanuele

AU - Schuurman, H.-J.

N1 - Acceptance in SAN (author didn't receive formal acceptance and this is closest to this). ET 3/10/18 AAM: author confirmed version, removed track changes. ET 2/10/18 AAM: No info in Sherpa, used 12m embargo as noted on webpage: 'Articles are generally available in full text after a 12-month delay (embargo); however, the delay may vary at the discretion of the publisher.' Exception form sent ET 8/10/18; author confirmed book chapter and provided exception information. Author email in SAN in case we need to use this later. ET 9/10/18

PY - 2018/4/30

Y1 - 2018/4/30

N2 - The main benefit of xenotransplantation is its potential to overcome the worldwide organ shortage experienced in allotransplantation. Allogeneic transplantation is the only successful therapy for several life-threatening diseases, with cell, tissue or organ donation only partially meeting the demand and many patients dying while waiting for treatment. With supply falling short of demand, it is foreseen that the use of porcine material may at some stage overcome the existing gap between organ availability and clinical need. Recently, pig islet cells have been utilised in clinical trials, with safety being demonstrated. Indeed, pig-derived cells present several advantages: i) porcine cells have a stable function and differentiation pattern and are not tumorigenic; ii) pig cells have been shown to meet the physiological needs in large animal models; iii) the source of pig cells can be scaled up to meet demands in a highly standardised manner, and with respect to animal welfare regulations; iv) ‘designated-pathogen-free’ (DPF) pig lines can be produced, which could result in a higher safety profile than allotransplantation itself; v) the risk of zoonosis, which was raised years ago as the major hurdle, has been recently circumvented and is actually viewed as a controlled risk; and vi) immune risks are being circumvented via the use of genetically modified donor animals and encapsulation of porcine cells, particularly for the treatment of diabetes. Overall, the benefit appears to outweigh potential risks with respect to cellular xenotransplantation and this is discussed further in this review.

AB - The main benefit of xenotransplantation is its potential to overcome the worldwide organ shortage experienced in allotransplantation. Allogeneic transplantation is the only successful therapy for several life-threatening diseases, with cell, tissue or organ donation only partially meeting the demand and many patients dying while waiting for treatment. With supply falling short of demand, it is foreseen that the use of porcine material may at some stage overcome the existing gap between organ availability and clinical need. Recently, pig islet cells have been utilised in clinical trials, with safety being demonstrated. Indeed, pig-derived cells present several advantages: i) porcine cells have a stable function and differentiation pattern and are not tumorigenic; ii) pig cells have been shown to meet the physiological needs in large animal models; iii) the source of pig cells can be scaled up to meet demands in a highly standardised manner, and with respect to animal welfare regulations; iv) ‘designated-pathogen-free’ (DPF) pig lines can be produced, which could result in a higher safety profile than allotransplantation itself; v) the risk of zoonosis, which was raised years ago as the major hurdle, has been recently circumvented and is actually viewed as a controlled risk; and vi) immune risks are being circumvented via the use of genetically modified donor animals and encapsulation of porcine cells, particularly for the treatment of diabetes. Overall, the benefit appears to outweigh potential risks with respect to cellular xenotransplantation and this is discussed further in this review.

KW - xenotransplantation

KW - animal cells

U2 - 10.20506/rst.37.1.2744

DO - 10.20506/rst.37.1.2744

M3 - Chapter (peer-reviewed)

SN - 978-92-95108-54-7

VL - 37

SP - 113

EP - 122

BT - Scientific and Technical Review

PB - OIE

ER -

Scobie L, Galli C, Gianello P, Cozzi E, Schuurman H-J. Cellular xenotransplantation of animal cells into people: benefits and risk. In Scientific and Technical Review. Vol. 37. OIE. 2018. p. 113-122 https://doi.org/10.20506/rst.37.1.2744